 | James D CoxShow email addressDepartment of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030-4009, Houston, TX, USA | MD Anderson Cancer Center, ... |
Is this your profile? Claim your profile Copy URL Embed Link to your profile |
James D Cox:Expert Impact
Concepts for whichJames D Coxhas direct influence:Radiation therapy,Lung cancer,Cell lung,Small cell,Esophageal cancer,Concurrent chemotherapy,Proton therapy,Induction chemotherapy.
James D Cox:KOL impact
Concepts related to the work of other authors for whichfor which James D Cox has influence:Lung cancer,Radiation therapy,Small cell,Brain metastases,Local control,Computed tomography.
KOL Resume for James D Cox
| Year | |
|---|---|
| 2018 | Department of Radiation Oncology, Unit 97, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, 77030-4009, Houston, TX, USA MD Anderson Cancer Center, Houston, Texas |
| 2017 | Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States |
| 2016 | The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2015 | Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA MD Anderson Cancer Center, Houston, TX |
| 2014 | M.D. Anderson Cancer Center, Houston, TX Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030 |
| 2013 | The University of Texas MD Anderson Cancer Center Department of Radiation Oncology Houston Texas USA |
| 2012 | Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas |
| 2011 | Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX |
| 2010 | Radiation Oncology, MD Anderson Cancer Center, Houston, TX |
| 2009 | Department of Radiation Oncology and Department of Radiation Physics, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston Texas 77030 MD Anderson Cancer Center, Houston, TX, USA Division of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas |
| 2008 | Department of Radiation Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, TX |
| 2007 | U.T.M.D. Anderson Cancer Center, Houston, TX The University of Texas M. D. Anderson Cancer Center, Houston, Texas. Department of Radiation Oncology, and |
| 2006 | University of Texas M.D. Anderson Cancer Center, Houston, TX Departments of Radiation Oncology |
| 2005 | Radiation Oncology, M. D. Anderson Cancer Center, Houston, TX and Division of Radiology, Kobe University Graduate School of Medicine, Hyogo, Japan |
| 2004 | Division of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA 3D Quality Assurance Center at Washington University St. Louis, MO From the Departments of *Radiation Oncology, †Biomathematics, and ‡Lymphoma, The University of Texas M. D. Anderson Cancer Center, Houston, Texas. Radiation Oncology, UT MD Anderson Cancer Center, Houston, TX |
| 2003 | Department of Radiation Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas Radiation Oncology, St. Joseph Medical Center, Stockton, CA, USA |
| Concept | World rank |
|---|---|
| tnm sccl | #1 |
| t1418q32q21 mbr | #1 |
| topic neoplasms neoplasms | #1 |
| median survival cti | #1 |
| approved programs | #1 |
| doses lung | #1 |
| initial evaluation time | #1 |
| delays 5 | #1 |
| 80 bulky lymphomas | #1 |
| alignment target prostate | #1 |
| 105 registration | #1 |
| excessive margin protocol | #1 |
| lung tumor location | #1 |
| dfs hormone therapy | #1 |
| univariate analyses age | #1 |
| protocol margins | #1 |
| tumor score predictor | #1 |
| patients locoregional adenocarcinoma | #1 |
| cmt stage iie | #1 |
| iii follicular lymphoma | #1 |
| fields involvedfield | #1 |
| registration bm | #1 |
| std lung | #1 |
| conebeam kilovoltage | #1 |
| alignment methods prostate | #1 |
| grade positive correlation | #1 |
| radiation therapy addition | #1 |
| bned diseasefree survival | #1 |
| greater 45 hours | #1 |
| quality clinical cancer | #1 |
| disease initial site | #1 |
| irradiation combined treatment | #1 |
| radiation conformality | #1 |
| lphd radiotherapy | #1 |
| daily interfraction interval | #1 |
| patients composite doses | #1 |
| dose levels levels | #1 |
| skin bone alignments | #1 |
| grade v75 | #1 |
| prostate ptv patients | #1 |
| patients 696 | #1 |
| cfid | #1 |
| analysis variance antineoplastic | #1 |
| fractional dose differences | #1 |
| 18 fraction 74 | #1 |
| 17 patients dlcl | #1 |
| ffp cmt | #1 |
| –volume modeling | #1 |
| accelerated proliferation hfx | #1 |
| surgery younger women | #1 |
| Sign-in to see all concepts, it's free! | |
Prominent publications by James D Cox
Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406
[ PUBLICATION ]
PURPOSE: A prospective Phase I dose escalation study was conducted to determine the maximally-tolerated radiation dose in men treated with three-dimensional conformal radiation therapy (3D CRT) for localized prostate cancer. This is a preliminary report of toxicity encountered on the 3DOG/RTOG 9406 study.
METHODS AND MATERIALS: Each participating institution was required to implement data exchange with the RTOG 3D quality assurance (QA) center at Washington University in St. Louis. 3D ...
| Known for Dose Level | 2 Patients | Late Toxicity | Preliminary Report | Radiation Therapy |
PURPOSE: To assess the association of clinical and especially dosimetric factors with the incidence of postoperative pulmonary complications among esophageal cancer patients treated with concurrent chemoradiation therapy followed by surgery.
METHOD AND MATERIALS: Data from 110 esophageal cancer patients treated between January 1998 and December 2003 were analyzed retrospectively. All patients received concurrent chemoradiotherapy followed by surgery; 72 patients also received ...
| Known for Dosimetric Factors | Pulmonary Complications | Esophageal Cancer Patients | Volume Lung | Multivariate Analysis |
PURPOSE: To calculate treatment plans and compare the dose distributions and dose-volume histograms (DVHs) for photon three-dimensional conformal radiation therapy (3D-CRT), electron therapy, intensity-modulated radiation therapy (IMRT), and standard (nonintensity modulated) proton therapy in three pediatric disease sites.
METHODS AND MATERIALS: The tumor volumes from 8 patients (3 retinoblastomas, 2 medulloblastomas, and 3 pelvic sarcomas) were studied retrospectively to compare DVHs ...
| Known for 3dcrt Imrt | Treatment Planning | Computerassisted Radiotherapy | Electron Therapy | Posterior Fossa |
Toxicity after three-dimensional radiotherapy for prostate cancer with RTOG 9406 dose level IV
[ PUBLICATION ]
PURPOSE: This is the first report of the toxicity outcomes using dose level IV (74 Gy) on Radiation Therapy Oncology Group (RTOG) study 9406 for Stage T1-T2 prostate adenocarcinoma.
METHODS AND MATERIALS: A total of 262 patients were entered in this cooperative group, Phase I-II, dose-escalation trial of three-dimensional conformal radiotherapy for localized prostate carcinoma treated to a dose of 74 Gy (Level IV); 256 patients were analyzable for toxicity. A minimal dose of 2 ...
| Known for Dose Level | 2 Patients | Prostate Cancer | Dimensional Radiotherapy | Radiation Follow |
Toxicity after three-dimensional radiotherapy for prostate cancer on RTOG 9406 dose Level V
[ PUBLICATION ]
PURPOSE: This is the first report of toxicity outcomes at dose Level V (78 Gy) on Radiation Therapy Oncology Group 9406 for Stages T1-T2 adenocarcinoma of the prostate.
METHODS AND MATERIALS: A total of 225 patients were entered in this cooperative group, Phase I-II dose-escalation trial of three-dimensional conformal radiotherapy for localized carcinoma of the prostate treated to a dose of 78 Gy (Level V). Of these patients, 219 were analyzed for acute and 218 for late toxicity. A ...
| Known for Dose Level | Late Toxicity | Patients Prostate | Grade 2 | Rtog 9406 |
BACKGROUND: Results from phase II studies in patients with stage IIIA non-small-cell lung cancer with ipsilateral mediastinal nodal metastases (N2) have shown the feasibility of resection after concurrent chemotherapy and radiotherapy with promising rates of survival. We therefore did this phase III trial to compare concurrent chemotherapy and radiotherapy followed by resection with standard concurrent chemotherapy and definitive radiotherapy without resection.
METHODS: Patients with ...
| Known for Phase Iii | Chemotherapy Radiotherapy | Lung Cancer | 5 Years | Surgical Resection |
BACKGROUND: The current study was performed to assess the value of 2-fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in predicting the pathologic response and survival of patients with esophageal carcinoma treated with preoperative chemoradiation (CRT) and tumor resection. Preliminary reports suggest that FDG-PET may be predictive of the response of esophageal carcinoma patients to preoperative CRT.
METHODS: Eighty-three patients with resectable esophageal carcinoma who ...
| Known for Pathologic Response | Esophageal Carcinoma | Preoperative Chemoradiation | Emission Tomography | Crt Fdgpet |
PURPOSE: In search of reliable biologic markers to predict the risk of normal tissue damage by radio(chemo)therapy before treatment, we investigated the association between single nucleotide polymorphisms (SNPs) in the transforming growth factor 1 (TGFbeta1) gene and risk of radiation pneumonitis (RP) in patients with non-small-cell lung cancer (NSCLC).
PATIENTS AND METHODS: Using 164 available genomic DNA samples from patients with NSCLC treated with definitive radio(chemo)therapy, we ...
| Known for Definitive Radiotherapy | Radiation Pneumonitis | Cell Lung | Single Nucleotide | Tgfβ1 Gene |
PURPOSE: Intrathoracic recurrence of non-small cell lung cancer (NSCLC) after initial treatment remains a dominant cause of death. We report our experience using proton beam therapy and intensity modulated radiation therapy for reirradiation in such cases, focusing on patterns of failure, criteria for patient selection, and predictors of toxicity.
METHODS AND MATERIALS: A total of 102 patients underwent reirradiation for intrathoracic recurrent NSCLC at a single institution. All doses ...
| Known for Proton Beam Therapy | Cell Lung | Intensity Modulated | Local Organs | Definitive Reirradiation |
Preliminary evaluation of low-grade toxicity with conformal radiation therapy for prostate cancer on RTOG 9406 dose levels I and II
[ PUBLICATION ]
PURPOSE: To evaluate the rates of low-grade late effects in patients treated for prostate cancer on Radiation Therapy Oncology Group (RTOG) 9406.
MATERIALS AND METHODS: Between August 1994 and September 1999, 424 patients were entered on this dose escalation trial of three-dimensional conformal radiation therapy (3D-CRT) for localized adenocarcinoma of the prostate at doses of 68.4 Gy (level I) and 73.8 Gy (level II). We have previously reported Grade 3 or greater late toxicity of ...
| Known for Dose Level | Prostate Cancer | Radiation Therapy | Grade Toxicity | 24 Patients |
PURPOSE: To compare dose volume histograms of intensity-modulated proton therapy (IMPT) with those of intensity-modulated radiation therapy (IMRT) and passive scattering proton therapy (PSPT) for the treatment of stage IIIB non-small-cell lung cancer (NSCLC) and to explore the possibility of individualized radical radiotherapy.
METHODS AND MATERIALS: Dose volume histograms designed to deliver IMRT at 60 to 63 Gy, PSPT at 74 Gy, and IMPT at the same doses were compared and the use of ...
| Known for Normal Tissue | Modulated Proton | Cell Lung | Radiation Therapy | Imrt Impt |
PURPOSE: To compare dose-volume histograms (DVH) in patients with non-small-cell lung cancer (NSCLC) treated by photon or proton radiotherapy.
METHODS AND MATERIALS: Dose-volume histograms were compared between photon, including three-dimensional conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT), and proton plans at doses of 66 Gy, 87.5 Gy in Stage I (n=10) and 60-63 Gy, and 74 Gy in Stage III (n=15).
RESULTS: For Stage I, the mean total lung V5, V10, and ...
| Known for Proton Radiotherapy | Stage Iii | Modulated Radiation | Dose Escalation | Cell Lung |
PURPOSE: To analyze the impact of involved field radiotherapy on local control, freedom from progression, and overall survival in patients with clinical Stage III-IV, intermediate grade, or large-cell immunoblastic lymphomas that responded to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP)-based induction chemotherapy.
METHODS AND MATERIALS: From July 1989 through October 1996, 32 patients with clinical Stage III and 27 patients with clinical Stage IV, intermediate ...
| Known for Involved Field Radiotherapy | Local Control | Patients Chemotherapy | Stage Iii | Large Cell |
